Section Arrow
IFRX.NASDAQ
- InflaRx NV
(Financial Status)
Quotes are at least 15-min delayed:2026/03/28 00:18 EDT
Regular Hours
Last
 0.9119
-0.0181 (-1.95%)
Day High 
0.9595 
Prev. Close
0.93 
1-M High
1.07 
Volume 
254.66K 
Bid
0.8515
Ask
0.9499
Day Low
0.875 
Open
0.91 
1-M Low
0.81 
Market Cap 
63.00M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.94 
20-SMA 0.94 
50-SMA 0.92 
52-W High 1.94 
52-W Low 0.7113 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.68/-0.63
Enterprise Value
63.65M
Balance Sheet
Book Value Per Share
0.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
29.33K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ITRMIterum Therapeutics plc0.0356-0.1404-79.77%-- 
ARTLArtelo Biosciences Inc10.54+7.35+230.41%-- 
ONCOOnconetix Inc1.94-1.28-39.75%0PE
RCKTRocket Pharmaceuticals3.77-0.92-19.62%-- 
ADMAADMA Biologics9.25+0.96+11.58%13.87PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.